Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Travere Therapeutics, Inc. (TVTX) provides access to the company’s official disclosures as a Nasdaq‑listed biopharmaceutical issuer focused on rare kidney, liver and metabolic diseases. Travere files periodic and current reports with the U.S. Securities and Exchange Commission under the Securities Exchange Act of 1934.
Recent Form 8‑K filings document press releases announcing quarterly and preliminary annual financial results, including net product sales and other financial metrics, as well as broader corporate updates. These reports specify when information is being furnished rather than filed for purposes of Section 18 of the Exchange Act and clarify that such information is not automatically incorporated by reference into registration statements unless expressly stated.
Travere also uses Form 8‑K to report material regulatory developments. For example, the company has filed 8‑Ks describing FDA communications on the supplemental New Drug Application (sNDA) for FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS), including the decision that an advisory committee meeting was no longer needed and confirmation of the Prescription Drug User Fee Act (PDUFA) target action date. Another 8‑K notes the FDA’s extension of the review timeline after the company submitted additional information characterized as a Major Amendment.
Through this page, users can review Travere’s financial reporting (10‑K and 10‑Q when available), current reports on significant events (8‑K), and other disclosures that describe the company’s clinical programs, commercial activities, risk factors and capital structure. Stock Titan enhances these filings with AI‑powered summaries that highlight key points in lengthy documents, helping readers quickly understand topics such as revenue drivers, R&D spending, regulatory interactions and forward‑looking statements. Real‑time updates from EDGAR and access to insider and executive transaction reports, when filed on forms such as Form 4, allow investors to monitor how management actions and regulatory events intersect with Travere’s strategy in rare diseases.
A shareholder filed a Rule 144 notice to sell 7,310 shares of common stock, with an aggregate market value of
A holder of common stock has filed a notice of intent to sell 7,175 shares of TVTX on the NASDAQ, with Morgan Stanley Smith Barney as broker. These shares were acquired on 01/31/2026 through restricted stock unit vesting as compensation from the issuer.
The filing notes that 89,472,327 common shares were outstanding and that, in the prior three months, Elizabeth E. Reed sold 10,000 common shares on 01/20/2026 for gross proceeds of 273,420. The seller represents they are not aware of any undisclosed material adverse information about the issuer.
Sandra Calvin has filed a Rule 144 notice to sell 4,333 shares of TVTX common stock through Morgan Stanley Smith Barney on or about 02/03/2026 on NASDAQ, with an indicated aggregate market value of $139,177.16.
These shares were acquired on 01/31/2026 via restricted stock unit vesting from the issuer as compensation. The filing also lists prior sales over the past three months: 67,115 shares on 11/04/2025 for gross proceeds of $2,416,140.00, 2,910 shares on 12/15/2025 for $104,760.00, and 7,402 shares on 12/24/2025 for $296,080.00.
Christopher Cline filed notice of a planned sale of 7,242 shares of common stock of TVTX, with an aggregate market value of $232,616.03. The shares are to be sold on February 3, 2026 on the NASDAQ through Morgan Stanley Smith Barney.
The 7,242 shares were acquired on January 31, 2026 through restricted stock unit vesting from the issuer as compensation. Over the prior three months, Cline sold 20,000 common shares on December 1, 2025, generating $700,202.00 in gross proceeds.
TVTX insider Jula Inrig has filed a Form 144 indicating an intent to sell 6,956 shares of common stock through Morgan Stanley Smith Barney on or about 02/03/2026 on the NASDAQ, with an aggregate market value of $223,429.38. The shares were acquired on 01/31/2026 via restricted stock unit vesting from the issuer as compensation.
Over the prior three months, Jula Inrig sold additional common shares in three transactions: 445 shares for $16,798.75, 2,031 shares for $81,605.58, and 15,000 shares for $630,004.50. The filing also notes a representation that the seller is not aware of undisclosed material adverse information about the issuer.
Travere Therapeutics CEO Eric M. Dube reported multiple equity transactions. On January 31, 2026, he acquired 113,800 shares of common stock at $0 through restricted stock units and received an option for 303,600 shares at an exercise price of $33.095 per share.
On February 3, 2026, he sold 66,452 shares at $32.06 and 33,635 shares at $32.70 under a pre-arranged Rule 10b5-1 trading plan, which also covered tax obligations from vesting. After these transactions, he directly held 432,886 common shares and 303,600 stock options.
Travere Therapeutics’ chief medical officer, Jula Inrig, reported equity grants and a tax-related share sale. On 01/31/2026, she acquired 28,130 shares of common stock at
That same day she received an employee stock option for 75,000 shares of common stock at an exercise price of
Travere Therapeutics' Chief Financial Officer Christopher R. Cline reported equity compensation activity and a related share sale. On January 31, 2026, he acquired 28,130 shares of common stock for $0 upon settlement of restricted stock units and held 120,213 shares afterward.
That same day he received an employee stock option for 75,000 shares at an exercise price of $33.095, expiring on January 31, 2036, with one-fourth vesting after one year and the rest vesting in 36 monthly installments. On February 3, 2026, he sold 7,242 shares at $32.12 per share to cover tax withholding from the vested restricted stock units, leaving him with 112,971 directly owned shares; the filing notes this was a mandated “sell to cover” transaction, not a discretionary trade.
Travere Therapeutics, Inc. Chief Commercial Officer Peter Heerma reported equity transactions in company stock. On January 31, 2026, he acquired 26,120 shares of common stock at $0 per share in connection with restricted stock units, bringing his direct holdings to 139,133 shares.
That same day, he received an employee stock option grant for 69,640 shares at an exercise price of $33.095 per share, vesting over four years. On February 3, 2026, he sold 7,310 shares at $32.12 per share to cover tax withholding owed on vested restricted stock units. The sale was executed under a mandatory "sell to cover" arrangement and is not described as a discretionary trade. After this sale, he directly held 131,823 shares of Travere common stock.
Travere Therapeutics Chief Research Officer William E. Rote reported routine equity compensation and a planned share sale. On 01/31/2026 he acquired 20,090 shares of common stock for $0 through restricted stock units and received an employee stock option for 53,570 shares at an exercise price of $33.095 per share.
These options vest over time, with one-fourth vesting on the first anniversary of grant and the remainder in 36 monthly installments. On 02/03/2026 he sold 12,446 shares of common stock at $32.87 per share under a Rule 10b5-1 trading plan, and held 109,087 common shares and 53,570 options directly afterward.
FAQ
What is the current stock price of Travere Therapeutics (TVTX)?
What is the market cap of Travere Therapeutics (TVTX)?
